Basic Information
| RNALocate ID: | RLID:11003649 |
| RNA Symbol: | hsa-miR-30c-2-3p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-30c-2-star |
| RNA ID: | miRBase:MIMAT0004550 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23539611 |
| Tissue/Cell Line: | Seminal plasma |
| Method: | Microarray |
| Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002590 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:11003647 | Exosome | B cell line (Raji)|Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11003648 | Exosome | Plasma | 23663360 |
| RLID:11003650 | Microvesicle | Serum | 24797360 |
| RLID-D:11000597 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
| RLID-D:11001476 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-30c-2-3p | Oral squamous cell carcinoma | MNDR-E-MI-37184 |
| MNDR | hsa-miR-30c-2-3p | Large cell neuroendocrine cancer | MNDR-E-MI-37185 |
| MNDR | hsa-miR-30c-2-3p | Ovarian clear cell carcinoma | MNDR-E-MI-37186 |
| MNDR | hsa-miR-30c-2-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-37187 |
| MNDR | hsa-miR-30c-2-3p | Lymphoma | MNDR-E-MI-37188 |
| MNDR | hsa-miR-30c-2-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-37189 |
| MNDR | hsa-miR-30c-2-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-37190 |
| MNDR | hsa-miR-30c-2-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-37191 |
| MNDR | hsa-miR-30c-2-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-37192 |
| MNDR | hsa-miR-30c-2-3p | Her2-receptor positive breast cancer | MNDR-E-MI-37193 |
| MNDR | hsa-miR-30c-2-3p | Prostate cancer | MNDR-E-MI-37194 |
| MNDR | hsa-miR-30c-2-3p | Gastric cancer | MNDR-E-MI-37195 |
| MNDR | hsa-miR-30c-2-3p | Alzheimer disease | MNDR-E-MI-37196 |
| MNDR | hsa-miR-30c-2-3p | Intracranial aneurysm | MNDR-E-MI-37197 |
| MNDR | hsa-miR-30c-2-3p | Bladder cancer | MNDR-E-MI-37198 |
| MNDR | hsa-miR-30c-2-3p | Esophageal carcinoma | MNDR-E-MI-37199 |
| MNDR | hsa-miR-30c-2-3p | Parkinson disease | MNDR-E-MI-37200 |
| MNDR | hsa-miR-30c-2-3p | Breast cancer | MNDR-E-MI-37201 |
| MNDR | hsa-miR-30c-2-3p | Thyroid cancer | MNDR-E-MI-37202 |
| MNDR | hsa-miR-30c-2-3p | Pancreatic cancer | MNDR-E-MI-37203 |
| MNDR | hsa-miR-30c-2-3p | Melanoma | MNDR-E-MI-37204 |
| MNDR | hsa-miR-30c-2-3p | Rectum adenocarcinoma | MNDR-E-MI-37205 |
| MNDR | hsa-miR-30c-2-3p | Nephroblastoma | MNDR-E-MI-37206 |
| MNDR | hsa-miR-30c-2-3p | Colon cancer | MNDR-E-MI-37207 |
| MNDR | hsa-miR-30c-2-3p | Colon adenocarcinoma | MNDR-E-MI-37208 |
| MNDR | hsa-miR-30c-2-3p | Familial ovarian cancer | MNDR-E-MI-37209 |
| MNDR | hsa-miR-30c-2-3p | Prostate adenocarcinoma | MNDR-E-MI-37210 |
| MNDR | hsa-miR-30c-2-3p | Kidney cancer | MNDR-E-MI-37211 |
| MNDR | hsa-miR-30c-2-3p | Carcinoma ductal breast | MNDR-E-MI-37212 |
| MNDR | hsa-miR-30c-2-3p | Glioma | MNDR-E-MI-37213 |
| MNDR | hsa-miR-30c-2-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-37214 |
| MNDR | hsa-miR-30c-2-3p | Gastric adenocarcinoma | MNDR-E-MI-37215 |
| MNDR | hsa-miR-30c-2-3p | Cervical squamous cell carcinoma | MNDR-E-MI-37216 |
| MNDR | hsa-miR-30c-2-3p | Lung squamous cell carcinoma | MNDR-E-MI-37217 |
| MNDR | hsa-miR-30c-2-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-37218 |
| MNDR | hsa-miR-30c-2-3p | Lung adenocarcinoma | MNDR-E-MI-37219 |
| MNDR | hsa-miR-30c-2-3p | Thyroid carcinoma | MNDR-E-MI-37220 |
| MNDR | hsa-miR-30c-2-3p | Bladder urothelial carcinoma | MNDR-E-MI-37221 |
| MNDR | hsa-miR-30c-2-3p | Pancreatic adenocarcinoma | MNDR-E-MI-37222 |
| MNDR | hsa-miR-30c-2-3p | Carcinoma renal cell | MNDR-E-MI-37223 |
| MNDR | hsa-miR-30c-2-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-37224 |
| MNDR | hsa-miR-30c-2-3p | Renal clear cell carcinoma | MNDR-E-MI-37225 |
| MNDR | hsa-miR-30c-2-3p | Biliary tract cancer | MNDR-E-MI-37226 |
| MNDR | hsa-miR-30c-2-3p | Cholangiocarcinoma | MNDR-E-MI-37227 |
| MNDR | hsa-miR-30c-2-3p | Lung small cell carcinoma | MNDR-E-MI-37228 |
| MNDR | hsa-miR-30c-2-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-37229 |
| MNDR | hsa-miR-30c-2-3p | Breast invasive carcinoma | MNDR-E-MI-37230 |
| MNDR | hsa-miR-30c-2-3p | Progressive supranuclear palsy | MNDR-E-MI-37231 |
| MNDR | hsa-miR-30c-2-3p | Hepatocellular carcinoma | MNDR-E-MI-37232 |
| MNDR | hsa-miR-30c-2-3p | Familiar ovarian carcinoma | MNDR-E-MI-37233 |
| MNDR | hsa-miR-30c-2-3p | Skin cutaneous melanoma | MNDR-E-MI-37234 |
| MNDR | hsa-miR-30c-2-3p | Skin melanoma | MNDR-E-MI-37235 |
| MNDR | hsa-miR-30c-2-3p | Colorectal cancer | MNDR-E-MI-37236 |
| MNDR | hsa-miR-30c-2-3p | Nasopharynx carcinoma | MNDR-E-MI-37237 |
| MNDR | hsa-miR-30c-2-3p | Nasopharyngeal cancer | MNDR-E-MI-37238 |
| MNDR | hsa-miR-30c-2-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-37239 |
| MNDR | hsa-miR-30c-2-3p | Breast cancer her3+ negative | MNDR-E-MI-37240 |
| MNDR | hsa-miR-30c-2-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-37241 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ATF3 | Homo sapiens | RR00155508 |
TOP